News – Page 95 – Endpoints News

FDA to reconsider removal of Lilly's GLP-1 drug from shortage list, a win for compounding pharmacies

8 months ago

Pfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma; Nobel Prizes highlight AI era

8 months ago

Pfizer gets an FDA win in hemophilia after a rough week

8 months ago

Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine

8 months ago

Stealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare disease drug

8 months ago

Sanofi lands on private equity firm CD&R as potential buyer of consumer health unit

8 months ago

Teva to pay $450M to settle allegations of kickbacks and generic drug price-fixing

8 months ago

European drugmakers look to reshore manufacturing but warn of price hikes

8 months ago

Perspective’s early data on lead-based radiopharma asset suggest lower dose did better

8 months ago

Turnstone rejigs staff and exec team, eases preclinical work as cash runs low

8 months ago

VC firm targets $35M second fund to back startups led by scientists

8 months ago

Exclusive: PhRMA attacks federal government's response to rebate model for 340B

8 months ago

Lilly follows the trend of new AI hires; Pfizer fills key UK position as activist hubbub swells

8 months ago

Biotech startups Upstream and CAMP4 price Friday IPOs

8 months ago

Sanofi discontinues Denali-partnered MS trial after Phase 2 failure

8 months ago

FDA adcomm supports first potential drug for ultra-rare, fatal Barth syndrome

8 months ago

Updated: FDA approves Roche's new treatment for subset of breast cancer patients

8 months ago

Seven patients diagnosed with blood cancer after Skysona treatment, new data show

8 months ago

Eli Lilly inks another obesity pact, doubling down on small Swiss partner

8 months ago

Immatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M

8 months ago

Sen. Warren urges FTC to ‘carefully scrutinize’ Novo-Catalent deal over competition concerns

8 months ago

Baxter plots recovery after Hurricane Helene, MilliporeSigma’s €290M facility

8 months ago

Exclusive: How an accidental email tipped Pfizer off to an activist investor’s plan

8 months ago

AI biotechs Recursion and Exscientia first held deal talks in 2022

8 months ago

First page Previous page 92 93 949596 97 98 Next page Last page